Introduction {#s1}
============

Human norovirus (HuNoV) is a major causative agent of gastroenteritis in humans (Green, [@B3]). The HuNoV genogroup II (GII), in particular, is frequently detected in outbreaks. The HuNoV GII strains can be classified into 22 genotypes (Kroneman et al., [@B6]). Moreover, the most worldwide prevalent HuNoV GII genotypes belong to GII genotype 2 (GII.2), GII.3, GII.4, GII.6, and GII.17 (Centers for Disease Control and Prevention. CaliciNet Data \[cited 2016\])[^1^](#fn0001){ref-type="fn"}. Since national surveillance began, nearly 3 million cases of NoV gastroenteritis have been recorded, and Japan was experiencing its second most serious norovirus outbreak during November 2016 to February 2017 (National Institute of Infectious Diseases. Japan. Infectious Gastroenteritis. \[cited 4th April 2017, in Japanese\])[^2^](#fn0002){ref-type="fn"} Importantly, HuNoV GII.2 emerged as a major cause of this outbreak in Japan, although the GII.4 strains were the most prevalent genotype during the past 10 years (National Institute of Infectious Diseases. Japan. Flash report of norovirus in Japan \[cited 4th April 2017, in Japanese\])[^3^](#fn0003){ref-type="fn"}.

Very recent studies suggested that the evolutionary patterns of human and animal NoV genotypes are distinct (Kobayashi et al., [@B5], [@B4]). Although all viral proteins may act as antigens, the HuNoV VP1 protein is also involved in viral infection. Furthermore, HuNoV frequently experiences recombination at the ORF1/ORF2 junction, resulting in new chimera viruses with different types of the RNA-dependent RNA polymerase (*RdRp*) genes and capsid (*VP1*) genes. Most studies have focused on the molecular evolution of HuNoV GII.4. Only a few examined that gene in other HuNoV genotypes, including GII.2. To gain insight into this process, we examined the molecular evolution of the GII.2 *RdRp* and *VP1* genes, including chimera viruses, based on the full genome analyses of those detected in Japan over a period of 10 years (2004--2015 seasons).

Materials and methods {#s2}
=====================

To investigate the molecular evolution of the HuNoV *VP1* and *RdRp* genes, 950 stool specimens were collected from various areas (13 prefectures) of Japan during the 2004--2015 seasons. These samples were obtained from patients with acute gastroenteritis due to HuNoV infections, in compliance with the Food Sanitation Law and the Law Concerning the Prevention of Infections and Medical Care for Patients of Infections of Japan. The personal data related to these samples were anonymized. RNA was extracted from 10% PBS suspensions of the specimens, and the HuNoV genomes were comprehensively analyzed by next-generation sequencing as described (Matsushima et al., [@B8]). Of 950 samples, the complete genome sequences of 538 strains were obtained (a success rate of 57%). Next, HuNoV genotypes were confirmed with the Norovirus Typing Tool (Version1.0), based on the nucleotide sequences of *RdRp* and *VP1* genes as described by Kroneman et al. ([@B7]). GII.2 strains were selected from these all genotyped strains, and then a few of strains having the undetermined base sequences (e.g., N, Y, R, and V) were omitted. Finally, 51 GII.2 strains were used for evolutionary analyses for the present study (Supplementary Table [1](#SM1){ref-type="supplementary-material"}). The obtained nucleotide sequences for the GII.2 strains were deposited in GenBank under the accession numbers [LC209431](LC209431) to [LC209481](LC209481).

Time-scale evolutionary analyses were performed using the Bayesian Markov Chain Monte Carlo method (MCMC) with the BEAST package v1.8.3 (Drummond and Rambaut, [@B2]) and Tracer[^4^](#fn0004){ref-type="fn"} as a demographic model. Substitution models were calculated with Kakusan4 (Tanabe, [@B9]). The substitution model for the *VP1* or the *RdRp* gene was the GTR-Γ or GTR-Γ invariant model, respectively. Based on Akaike\'s Information Criterion for MCMC values, we used the random local clock as a clock model, and used the logistic growth model (*VP1* gene) or the constant size model (*RdRp* gene) as a tree model. Convergence was evaluated with an effective sample size (acceptable more than 200). The MCMC chain length was 3 × 10^8^ steps with sampling every 1,000 steps for the MCMC tree of the *VP1* gene. To exactly estimate the evolutionary rates and topologies of the MCMC tree of the *RdRp* gene, we bound two independent data of the MCMC chains[^5^](#fn0005){ref-type="fn"}. The MCMC chain length was 2 × 10^8^ steps and 4 × 10^8^ with sampling every 5,000 steps for the MCMC tree of the *RdRp* gene. Statistical analyses were performed with the Welch\'s *t*-test in Excel 2013.

Results and discussion {#s3}
======================

Distribution of GII.2 genotype during the 2004--2015 seasons
------------------------------------------------------------

Four genotypes of the GII.2 strains, including GII.P2-GII.2 (13 strains), GII.Pe-GII.2 (one strain), GII.P12-GII.2 (one strain), and GII.P16-GII.2 (36 strains), were determined by the Norovirus Typing Tool (Figure [1](#F1){ref-type="fig"}). Of them, GII.P16-GII.2 strains were the most prevalent genotype after 2009. The single GII.P12-GII.2 and GII.Pe-GII.2 strains were detected in 2004 and 2014 respectively. The GII.P2-GII.2 strains were detected throughout the investigation periods.

![**Distribution of GII.2 genotype during the investigation periods (2004--2015 seasons)**.](fmicb-08-00705-g0001){#F1}

Phylogenetic analysis and evolutionary rates of *VP1* and *RdRp* virus genes
----------------------------------------------------------------------------

Based on the *VP1* gene sequences, we constructed a time-scale evolutionary tree (Figure [2A](#F2){ref-type="fig"}). The phylogeny of the *VP1* gene showed that GII.2 strains could be divided according to the type of *RdRp* gene. GII.P16-GII.2 could be subdivided into three clusters of strains in 2009--2010, 2010--2012, and 2012--2014. In addition, the phylogenetic divergence of the GII.P16-GII.2 strains might be wider than that of the GII.P2-GII.2 strains. The tree shows that the most recent common ancestor (MRCA) of the present GII.2 strains appeared in 1956 (mean ± 95% highest posterior densities \[HPD\]: 1945--1966). Subsequently, GII.P2-GII.2 virus strain emerged in 2000 (mean ± 95% HPD: 1998--2001). Moreover, the GII.P16-GII.2 strains detected in 2010--2012 diverged from a common ancestor of the GII.P2-GII.2 strains at 2002 (mean ± 95% HPD: 2001--2004). The GII.P16-GII.2 strains detected in 2009--2010 and 2012--2014 diverged at 2005 (mean ± 95% HPD: 2004--2007). The evolutionary rate of these *VP1* genes was 2.987 × 10^−3^ substitutions/site/year (mean ± 95% HPD: 2.496--3.486 × 10^−3^ substitutions/site/year).

![**Phylogenetic trees of *VP1* (A)** and *RdRp* **(B)** genes of the genotype GII.2 constructed by the Bayesian MCMC method. We analyzed *VP1* gene of 50 strains, and *RdRp* gene of 49 strains, excluding 100%---matched homologous strains. Reference strains in these trees were indicated in bold letters. Gray bar shows 95% HPD. The scale bar represents actual time (year).](fmicb-08-00705-g0002){#F2}

We also constructed a time-scale evolutionary tree of the *RdRp* gene (Figure [2B](#F2){ref-type="fig"}). The tree shows that the MRCA of *RdRp* of the present GII.2 strains was in the year 1696 (mean ± 95% HPD: 1542--1837). The common ancestor of the GII.P16-GII.2 strains diverged in 1858 (mean ± 95% HPD: 1747--1950) and formed two clusters. Moreover, the GII.P16-GII.2 strains detected in 2010--2012 diverged at 1989 (mean ± 95% HPD: 1972--2003), whereas the GII.P16-GII.2 strains detected in 2009--2010 and 2012--2014 diverged at 1986 (mean ± 95% HPD: 1968--2002). The common ancestor of the GII.P2-GII.2, GII.P12-GII.2, and GII.Pe-GII.2 diverged in 1828 (mean ± 95% HPD: 1741--1913). The *RdRp* gene of GII.P2-GII.2 diverged in 1992 (mean ± 95% HPD: 1984--2000). The evolutionary rate of these *RdRp* genes was 1.314 × 10^−3^ substitutions/site/year (mean ± 95% HPD: 0.698--1.95 × 10^−3^ substitutions/site/year).

Next, we compared the evolutionary rates of the GII.P16-GII.2 and GII.P2-GII.2 strains. To gain statistical significance, we collected the nucleotide sequences of the GII.P2-GII.2 strains (25 strains) from GenBank, but we could not collect a sufficient number of the GII.P12-GII.2 and GII.Pe-GII.2 sequences from the GenBank to reach statistical significance. The evolutionary rate of GII.P16-GII.2 (1.838 × 10^−3^ substitutions/site/year; mean ± 95% HPD: 1.237--2.456 × 10^−3^ substitutions/site/year) was greater than that of GII.P2-GII.2 (1.712 × 10^−3^ substitutions/site/year; mean ± 95% HPD: 0.957--2.41 × 10^−3^ substitutions/site/year) (*p* = 7.891 × 10^−135^).

A previous report suggested that the evolution of *VP1* may be influenced by the activities of *RdRp* (Bull et al., [@B1]). Collectively, our bioinformatics data also showed that the evolution of the GII.2 *VP1* gene was accelerated by a recombination of ORF1, including the *RdRp* gene. However, additional *in vitro* studies regarding the mutation rates of *RdRp* of the GII.P2 and GII.P16 may be needed to clarify the hypothesis of the relationships between and *VP1* and *RdRp* genes in this study. Furthermore, GII.2 variant strains were detected in the present season (2016/17 season), and thus, further genetic studies may be needed to prove this hypothesis.

Conclusions {#s4}
===========

Here we report the molecular evolution of the *VP1* and *RdRp* genes in HuNoV GII.2. Our main findings and hypothesis are as follows. (1) Four genotypes of GII.2 (GII.P2-GII.2, GII.P16-GII.2, GII.P12-GII.2, and GII.Pe-GII.2) were detected in Japan in 2004--2015. (2) A common ancestor of the current GII.2 virus strains circulated around 1956. (3) *VP1* gene evolution seems to depend on the *RdRp* gene. The *VP1* gene in a prevalent HuNoV genotype GII.2 might evolve uniquely by transfer of the *RdRp* gene.
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